ClinicalTrials.gg
RecruitingNCT06434766TMCPUpdated Aug 3, 2026

Multicenter iTBS Neuromodulation for PTSD Treatment

An interventional study of sham stimulation and intermittent theta-burst stimulation (iTBS) in Posttraumatic Stress Disorder, sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine. Recruiting at 5 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-03.

Sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 29 studies in Stress Disorders, Post-Traumatic with a site in China — 16 open to participants now, 19 under way, none of them phase 3. Stress Disorders, Post-Traumatic · China.

Planned enrollment
8th of 23
140 · median 120
Started
2024
with 4 others
No phase
23 of 29
14 open now
Primary completion
2026-12
later than 10 of 18 live
Registered
14th of 29
by date

Among the 29 studies in Stress Disorders, Post-Traumatic with a site in China, this one is the 8th largest by planned enrollment of the 23 interventional ones that give a count, is one of 5 that started in 2024, is one of 23 with no phase, reaches primary completion later than 10 of the 18 other live ones, and was the 14th registered.

Stress Disorders, Post-Traumatic

2,685 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 603 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

16 of the 29 studies in Stress Disorders, Post-Traumatic with a site in China are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 417 Stress Disorders, Post-Traumatic studies recruiting now, 187 (45%) set no upper age limit and 204 (49%) stop at 75 or younger; 63 take children under 18; 89 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Stress Disorders, Post-Traumatic with a site in China, or all of them as a file.
02

Study summary

The proposed study aims to evaluate the efficacy of intermittent theta-burst transcranial magnetic stimulation (iTBS) targeting primary motor cortex (M1) as adjunct treatment for PTSD patients. The primary outcome measure includes changes in PTSD symptom severity, with secondary outcome measures focusing on negative moods improvements, quality of life and social/occupation functioning and functional connectivity of the brain.

Read the detailed description

The proposed study aims to evaluate the efficacy of intermittent theta-burst transcranial magnetic stimulation (iTBS) targeting primary motor cortex as adjunct treatment for PTSD patients.

Compared to traditional repetitive transcranial magnetic stimulation (rTMS), iTBS strategy usually delivers large amounts of pulses in a shorter time period, and its equal efficiency has been demonstrated in several psychiatric disorders such as major depressive disorder (MDD). Through this adequately randomized and sham-controlled study of iTBS for PTSD, this work will provide an alternative and potentially more potent stimulation target for clinical PTSD treatment. This study will also provide a comprehensive assessment of this treatment strategy towards improvements in symptoms, quality of life and brain functioning in PTSD.

The ultimate goal of this study is to develop a non-invasive brain stimulation approach targeting a novel site for alleviating symptoms and improving life quality for PTSD patients.

03

Conditions studied

  • Posttraumatic Stress Disorder

Keywords

  • iTBS
  • PTSD
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged between 18 to 65 years old
  • Right handedness
  • Have a diagnosis of PTSD meeting criteria
  • CAPS-5 score>35
  • Under stable medication for at least four weeks
  • Capable of independently reading and understanding study materials and providing .

Exclusion criteria

Exclusion Criteria:

  • Current (or past if appropriate) significant neurological or medical disorder, or lifetime history of 1) seizure disorder; 2) primary or secondary CNS tumors; 3) stroke; or 4) cerebral aneurysm.
  • Primary psychotic disorder, bipolar I disorder, major depressive disorder, or personality disorders
  • Lifetime history of attempted suicide or HAMD-17 suicide item (item 3) ≥ 3 points
  • Implanted device (deep brain stimulation) or metal in the brain; a pacemaker, extensive dental work, or any magnetic metal implants and upper body tattoos if choose to do fMRI
  • Previous experience of rTMS
  • Pregnancy/lactation, or planning to become pregnant during the study
  • Current under psychological or other physical treatments
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
140 participants (estimated)

Study arms

  • Sham comparator
    Sham stimulation

    A sham coil with exactly the same appearance of active coil is used to compare with active coil. Stimulation dose and frequency is the same as active stimulation.

    Device: sham stimulation

  • Active comparator
    Active stimulation

    An active coil is used to deliver iTBS. The stimulation dose is 20 sessions (1800 pulses per session; 2 sessions a day, at least 1 hour apart) over the course of 2 weeks (10 days to 14 days, allow at most three breaks and only once of the longest interval of 2 days).

    Device: intermittent theta-burst stimulation (iTBS)

Interventions

  • Devicesham stimulation

    sham theta-burst transcranial magnetic stimulation

  • Deviceintermittent theta-burst stimulation (iTBS)

    intermittent theta-burst transcranial magnetic stimulation

06

What researchers measure

Primary outcomes

  1. Change in PTSD Symptom Severity

    Change in PTSD symptom severity measured by the Clinician Administered PTSD Scale for DSM-5 (CAPS-5). The CAPS-5 is a structured interview designed to make a categorical PTSD diagnosis, as well as to provide a measure of PTSD symptom severity. The structure corresponds to the DSM-5 criteria, with B, C, D and E symptoms rated for both frequency and intensity which are summed to provide severity ratings. Items rated '0' means 'absent' and item rated '4' means 'extreme/incapacitating'. Higher scores indicate more severe PTSD symptoms.

    Time frame: Baseline and 4 weeks after finishing treatment

Secondary outcomes

  1. Change in PTSD Symptom Severity

    Change in PTSD symptom severity measured by the Clinician Administered PTSD Scale for DSM-5 (CAPS-5).

    Time frame: Baseline, 10 times treatment, 20 times treatment, 2 weeks after finishing treatment and 8 weeks after finishing treatment

  2. Change in Post-traumatic Stress Disorder Checklist for DSM-5 (PCL-5) Total Score

    The PCL-5 is a 20-item self-report checklist of PTSD symptoms based closely on the DSM-5 criteria. Respondents rate each item from 0 ("not at all") to 4 ("extremely") to indicate the degree to which they have been bothered by that particular symptom over the past month (or past week if using the PCL-5 weekly). A total symptom severity score (range: 0-80) can be obtained by summing the scores for each of the 20 items, with higher scores indicating more severe PTSD symptoms.

    Time frame: Baseline, 10 times treatment, 20 times treatment, 2, 4 and 8 weeks after finishing treatment

  3. Change in The Quick Inventory of Depressive Symptomatology Self Report (QIDS-SR) Score

    The IDS-SR is a 30-item questionnaire measuring depressive symptoms. Each item has four statements that reflect various degrees of symptom severity, scored on a four-point scale from 0 to 3. The 16-item Quick Inventory of Depressive Symptomatology (QIDS) is a new measure of depressive symptom severity derived from the 30-item IDS-SR and has highly acceptable psychometric properties.

    Time frame: Baseline, 10 times treatment, 20 times treatment, 2, 4 and 8 weeks after finishing treatment

  4. Change in The Personal Social Performance (PSP) scale

    The Personal and Social Performance Scale (PSP) is a 100-point single-item rating scale that assesses four important domains of patients with mental disorders. The four main areas include (a) socially useful activities, including work and study; (b) personal and social relationships; (c) self-care; and (d) disturbing and aggressive behaviors.

    Time frame: Baseline, 10 times treatment, 20 times treatment, 2, 4 and 8 weeks after finishing treatment

  5. change in Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF)

    Q-LES-Q-SF is a patient-reported 16-item instrument that measures the degree of enjoyment and satisfaction in daily life over the past week. Individual items are rated on a scale from 1-5 ('very poor', 'poor', 'fair', 'good', or 'very good'). The Q-LES-Q-SF total score is the sum of the first 14 item scores (i.e. excluding medication satisfaction and overall life satisfaction and contentment) with a higher score indicating greater satisfaction (range = 14-70).

    Time frame: Baseline, 10 times treatment, 20 times treatment, 2, 4 and 8 weeks after finishing treatment

  6. Change in neural activity pattern and functional connectivity of the brain based on fMRI

    Structural, resting-state and task-based fMRI will be performed if the participant agree. During task-fMRI, the participant will listen to a script around one minute recorded during his/her first interview, describing the traumatic experience in details. The participant will be instructed to recall the traumatic experience vividly during the task-fMRI. Brain activity patterns and connectivity network will be presented and analyzed.

    Time frame: Baseline, 20 times treatment, 4 weeks after finishing treatment

07

Study locations

5 of 5 sites recruiting
  • Shanghai Mental Health Center
    Shanghai, Shanghai Municipality, China
    Recruiting
    • Binxin Huang, M.D., Ph.D. · Contacthuangbinxin2022@163.com · +86177 0179 5651
    • Zhen Wang, M.D., Ph.D. · Principal investigator
  • First Affiliated Hospital of Anhui Medical University
    Hangzhou, Zhejiang, China
    Recruiting
    • Gongjun Ji, Ph.D. · Contactjigongjun@163.com · +86055165167581
    • Kai Wang, M.D., Ph.D. · Principal investigator
  • Second Affiliated Hospital Zhejiang University School of Medicine
    Hangzhou, Zhejiang, China
    Recruiting
    • Huiqian Huang, Ph.D. · Contacthhq0301@zju.edu.cn · (+86)057188206092
    • Shanshan Li, Bachelor · Contact1252037349@qq.com · +8615867111248
    • Xiao-Ming Li, Ph.D., M.D. · Principal investigator
    • Huiqian Huang, Ph.D. · Sub investigator
  • The Affiliated Kangning Hospital of Ningbo University
    Ningbo, Zhejiang, China
    Recruiting
    • Wenhao Zhuang, M.D. · Contactzwhphil@163.com · +8615888178517
    • Chang Yu, M.D. · Principal investigator
  • Tongji Hospital of Tongji University
    Shanghai, China
    Recruiting
    • Xinchun Mei · Contactxinchun0416@163.com · 021-51030581
    • Yuan Shen, M.D., Ph.D. · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Dec 2026, 26 months after the start.

Of 1,065 non-industry interventional studies with no phase under Stress Disorders, Post-Traumatic, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 26 months is below that.

Counting every sponsor, half of 1,093 studies reached it within 34 months; a quarter within 17 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2024
First posted
May 30, 2024
StartActual
Oct 30, 2024
Primary completionEst.
Dec 2026
CompletionEst.
Jun 2027
Last update
Aug 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06434766
Collaborators
Shanghai Mental Health Center, The Affiliated Kangning Hospital of Ningbo University, The First Affiliated Hospital of Anhui Medical University, Tongji Hospital
Responsible party
Sponsor
First posted
May 30, 2024
Start date
Oct 30, 2024
Primary completion
Dec 2026 (estimated)
Completion
Jun 2027 (estimated)
Last update
Aug 3, 2026

Study contacts

Huiqian Huang, Ph.D.
Contact
hhq0301@zju.edu.cn
+8618757143725
Shanshan Li, Bachelor
Contact
1252037349@qq.com
Yuan Shen, M.D., Ph.D.
principal investigator · Tongji Hospital
Chang Yu, M.D.
principal investigator · The Affiliated Kangning Hospital of Ningbo University
Kai Wang, M.D., Ph.D.
principal investigator · The First Affiliated Hospital of Anhui Medical University
Xiaoming Li, M.D., Ph.D.
principal investigator · Second Affiliated Hospital, Zhejiang University, School of Medicine
Zhen Wang, M.D., Ph.D.
principal investigator · Shanghai Mental Health Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion